The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment.
Autor: | Ayoub NM; Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan. Electronic address: nmayoub@just.edu.jo., Siddique AB; Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA., Ebrahim HY; Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA., Mohyeldin MM; Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA., El Sayed KA; Department of Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | European journal of pharmacology [Eur J Pharmacol] 2017 Sep 05; Vol. 810, pp. 100-111. Date of Electronic Publication: 2017 Jun 15. |
DOI: | 10.1016/j.ejphar.2017.06.019 |
Abstrakt: | Luminal breast cancer represents a therapeutic challenge in terms of aggressive disease and emerging resistance to targeted therapy. (-)-Oleocanthal has demonstrated anticancer activity in multiple human cancers. The goal of this study was to explore the effect of (-)-oleocanthal treatment on growth of luminal breast cancer cells and to examine the effect of combination of (-)-oleocanthal with tamoxifen. Results showed that (-)-oleocanthal inhibited growth of BT-474, MCF-7, and T-47D human breast cancer cells in mitogen-free media with IC (Copyright © 2017 Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |